2-(4-硝基苯氧基)乙胺 | 60814-16-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(4-硝基苯氧基)乙胺
• 中文别名: 4-溴-1-氯-2-氟苯
• 英文名称: 4-Nitrophenyl 2-aminoethyl ether
• 英文别名: 2-(p-nitrophenoxy)ethylamine；p-nitrophenoxyethylamine；2-(4-Nitrophenoxy)-1-ethanamine；2-(4-nitrophenoxy)-ethylamine；2-(4-nitro-phenoxy)-ethylamine；2-(4-Nitro-phenoxy)-aethylamin；2-(4-Nitrophenoxy)ethanamine
• CAS: 60814-16-6
• 化学式: C₈H₁₀N₂O₃
• mdl: MFCD00634284
• 分子量: 182.179
• InChiKey: HIEVUCALPWFEFA-UHFFFAOYSA-N

物化性质

• 熔点：
  29-30℃
• 密度：
  1.252

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  81.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2922299090

反应信息

• 作为反应物：
  描述：

  2-(4-硝基苯氧基)乙胺 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 生成 4-(2-amino-ethoxy)-aniline
  参考文献：
  名称：

  Discovery of TD-4306, a long-acting β2-agonist for the treatment of asthma and COPD

  摘要：

  A multivalent approach focused on amine-based secondary binding groups was applied to the discovery of long-acting inhaled beta(2)-agonists. Addition of amine moieties to the neutral secondary binding group of an existing beta(2)-agonist series was found to provide improved in vivo efficacy, but also led to the formation of biologically active aldehyde metabolites which were viewed as a risk for the development of these compounds. Structural simplification of the scaffold and blocking the site of metabolism to prevent aldehyde formation afforded a potent series of dibasic beta(2)-agonists with improved duration of action relative to their monobasic analogs. Additional optimization led to the discovery of 29 (TD-4306), a potent and selective beta(2)-agonist with potential for once-daily dosing. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.04.095
• 作为产物：
  描述：

  2-氯乙基 4-硝基苯基醚 在 三苯基膦 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-(4-硝基苯氧基)乙胺
  参考文献：
  名称：

  Heterocyclic beta-3 adrenergic receptor agonists

  摘要：

  这项发明提供了具有结构式I的化合物 1 其中U、V、W、X和Y如前文所定义， 或其药学上可接受的盐，用于治疗或抑制与胰岛素抵抗或高血糖相关的代谢紊乱（通常与肥胖或葡萄糖不耐受有关）、动脉粥样硬化、胃肠道疾病、神经炎症、青光眼、眼压增高和频繁排尿；特别适用于治疗或抑制2型糖尿病。

  公开号：

  US20020028832A1

文献信息

• 액정 배향 처리제
  申请人：Nissan Chemical Corporation 닛산 가가쿠 가부시키가이샤(519980958906)

  公开号：KR20150138410A

  公开（公告）日：2015-12-09

  러빙 처리시의 막 표면에 대한 스크레치나 깎임이 적고, 액정의 배향성이 양호하고, 또한 액정 셀의 전압 유지율이 높고, 이온 밀도도 낮은 액정 배향막이 얻어지는 액정 배향 처리제를 제공한다. 디아민 성분과 테트라카르복실산 유도체를 반응시켜 얻어지는 폴리이미드 전구체 또는 폴리이미드의 어느 하나를 함유하는 액정 배향 처리제로서, 상기 디아민 성분은 하기 식 (1) 로 나타내는 디아민을 함유하는 것을 특징으로 하는 액정 배향 처리제. (식 (1) 중, X 는 산소 원자 또는 황 원자이고, Y 및 Y 는 각각 독립적으로, 단결합, -O-, -S-, -OCO-, 또는 -COO- 이고, R 및 R 는 각각 독립적으로 탄소수 1 ∼ 3 의 알킬렌기이다)

  提供了一种液晶取向处理剂，其在液晶取向处理时对阻挡层表面的划痕或磨损较少，液晶的取向性良好，并且液晶单元格的电压保持率高，离子密度低。液晶取向处理剂包含由二胺成分和四羧酸衍生物反应得到的聚酰亚胺树脂或聚酰亚胺的任意一种。上述二胺成分特征在于包含如下式(1)所示的二胺。式(1)中，X是氧原子或硫原子，Y和Y'各自独立地为单键，-O-, -S-, -OCO-, 或-COO-，R和R'各自独立地为碳数为1至3的烷基。
• Substituted phenyl sulfonamides as selective .beta. 3 agonists for the
  申请人：Merck & Co., Inc.

  公开号：US05451677A1

  公开（公告）日：1995-09-19

  Substituted phenylsulfonamides are selective .beta..sub.3 adrenergic receptor agonists with very little .beta..sub.1 and .beta..sub.2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent activity in the treatment of Type II diabetes and obesity. The compounds can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compounds can be used to reduced neurogenic inflammation or as antidepressant agents. The compounds are prepared by coupling an aminoalkylphenyl-sulfonamide with an appropriately substituted alkyl epoxide. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility are also disclosed.

  取代苯磺酰胺是选择性的β3肾上腺素受体激动剂，几乎没有β1和β2肾上腺素受体活性，因此这些化合物能够增加细胞内脂解和能量消耗。因此，这些化合物在治疗2型糖尿病和肥胖症方面具有强大的活性。这些化合物还可以用于降低甘油三酯水平和胆固醇水平，或提高高密度脂蛋白水平，或减少肠道蠕动。此外，这些化合物可以用于减少神经源性炎症或作为抗抑郁剂。这些化合物是通过将氨基烷基苯磺酰胺与适当取代的烷基环氧化合物偶联而制备的。还公开了这些化合物在治疗糖尿病和肥胖症以及降低甘油三酯水平和胆固醇水平或提高高密度脂蛋白水平或增加肠道蠕动方面的用途的组合物和方法。
• 用于抑制激酶活性的二苯氨基嘧啶类化合物
  申请人：深圳市塔吉瑞生物医药有限公司

  公开号：CN109232440B

  公开（公告）日：2020-09-11

  用于抑制激酶活性的二苯氨基嘧啶类化合物。本发明提供了一种取代的二苯氨基嘧啶类化合物的药物组合物及其用途，所述的化合物如式(I)所示化合物，或其药学上可接受的盐、前药、水合物或溶剂化合物、晶型、N‑氧化物和各种非对映体。本发明化合物可用于治疗可用JAK2激酶抑制剂治疗的疾病。
• Novel phenoxyalkylamine derivatives. V. Synthesis, .ALPHA.-blocking activity and quantitative structure-activity analysis of .ALPHA.-((phenoxyethylamino)propyl)-.ALPHA.-phenylacetonitrile derivatives.
  作者：KAZUYA MITANI、SHUNICHIRO SAKURAI、TOSHIHIRO SUZUKI、KOJI MORIKAWA、EIICHI KOSHINAKA、HIDEO KATO、YASUO ITO、TOSHIO FUJITA

  DOI：10.1248/cpb.36.4121

  日期：——

  α-[(Phenoxyethylamino) propyy]-α-phenylacetonitrile derivatives possessing various substituents on the benzene ring (A ring) at the phenylacetonitrile moiety, on the quaternary carbon atom and on the benzene ring (B ring) at the phenoxy moiety, and exhibiting various degrees of ablocking activity, were prepared. The variations in the activity were analyzed qualitatively as well as quantitatively by using physicochemical substituent parameters and a regression technique. The effect of substituents on the A ring was rationalized in terms of a parabolic function of their hydrophobic parameter. As regards substituents on the quaternary carbon atom, alkyl groups were desirable for high activity. The effects of substituents on the B ring were such that an optimum hydrophobic condition exists and that an alkoxy substituent at the o-position as well as smaller substituents at the m-and p-positions are favorable for high activity. The analysis for the combined series of analogs where substituents on the A and B rings are varied showed the existence of an optimum hydrophobicity for the whole molecule for the transport process of the molecule, besides above-mentioned various position-specific structural effects.

  合成了α-[(苯氧乙基氨基)丙基]-α-苯基乙腈衍生物，这些衍生物在苯乙腈部分的苯环（A环）上、在四面体碳原子上，以及在苯氧部分的苯环（B环）上，具有不同的取代基，并表现出各种程度的α-阻断活性。采用物理化学取代基参数及回归技术，对活性的变化进行了定性和定量分析。A环上取代基的影响根据其疏水参数的抛物线函数进行合理化。至于四面体碳原子上的取代基，烷基基团被认为是高活性的理想选择。B环上取代基的影响表明，存在一个最佳的疏水条件，并且在邻位的烷氧取代基以及在间位和对位的较小取代基有利于高活性。针对A环和B环取代基变化的综合系列类似物的分析显示，在分子的运输过程中，整个分子的最佳疏水性存在，此外也考虑了上述不同位置特异的结构效应。
• [EN] BENZOIMIDAZOLE DERIVATIVES AND GLYCOGEN SYNTHASE KINASE-3 BETA INHIBITORS CONTAINING THE SAME<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE ET INHIBITEURS DE GLYCOGÈNE SYNTHASE KINASE-3-BÊTA CONTENANT CEUX-CI
  申请人：ONCOTHERAPY SCIENCE INC

  公开号：WO2010014794A1

  公开（公告）日：2010-02-04

  Benzoimidazole Derivatives are provided. The compounds of the present invention are useful for Glycogen Synthase Kinase-3 Beta Inhibitors.

  苯并咪唑衍生物已提供。本发明的化合物对于糖原合成酶激酶-3β抑制剂是有用的。